⌕

Dexcom (DXCM) vs West Pharmaceutical Services (WST)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
60
West Pharmaceutical Services, Inc.
$416.42 · $29B
Strongest balance sheetCalmest ride
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is total return.

#2 FIT
55
Dexcom Inc
$83.33 · $31B
Fastest growerStreet favoriteHighest quality
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is growth.

WST edges ahead (60/100 vs DXCM 55) under a balanced style, mostly on total return. But DXCM wins on growth, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorDXCMWST
Overall fit score
weighted for your balanced goal
55
7 of 8 factors known
✓ 60
Valuation
Cheaper for what you get
1×
✓ P/E 33 · EV/EBITDA 26.1
P/E trailing
36
P/E 53 · EV/EBITDA 38.0
P/E trailing
20
Growth
Revenue & earnings momentum
1×
✓ —
70
—
53
Profitability & quality
Margins & return on capital
1×
✓ Net 19% · ROIC 25%
TTM through Sep 30, 2026
76
Net 17% · ROIC 17%
TTM through Jun 30, 2026
69
Total return
Share-price change with dividends reinvested
1×
5Y −12%/yr
30
✓ 5Y +0%/yr
54
Risk (calm = better)
Volatility & drawdown
1×
β 1.1 · DD −66%
60
✓ β 0.8 · DD −59%
73
Balance sheet†
Debt vs cash cushion
1×
Net debt/EBITDA −0.7×
fiscal 2025
41
✓ Net debt/EBITDA −0.8×
fiscal 2025
65
Dividend & income
Cash paid to you
1×
—
—
✓ 0.21% yield· A
80
Analyst sentiment
Forward EPS growth (consensus)
1×
✓ Est EPS +16%/yr · 15 analysts
74
Est EPS +9%/yr · 10 analysts
64
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafety
Income axis omitted: no data for one of these stocks.
■ DXCM■ WST
CAN YOU STOMACH THE RIDE?
Worst drawdownBeta (vs market)VolatilityHistory
DXCM−66%1.1447%5Y
WST−59%0.8141%5Y
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on growth: — (score 70).

▲ Leads on analyst sentiment: Est EPS +16%/yr · 15 analysts (score 74).

BEAR CASE

▼ Weakest on total return: 5Y −12%/yr (score 30).

▼ Weakest on balance sheet (score 41). Net debt/EBITDA −0.7× is one of the 5 inputs.

BULL CASE

▲ Leads on balance sheet (score 65). Net debt/EBITDA −0.8× is one of the 5 inputs.

▲ Leads on risk (calm = better): β 0.8 · DD −59% (score 73).

BEAR CASE

▼ Weakest on growth: — (score 53).

▼ Weakest on valuation: P/E 53 · EV/EBITDA 38.0 (score 20).

WHAT COULD CHANGE THE SCORE
Total returnCurrently 30/100 (5Y −12%/yr). Taking it to 100 would lift the balanced score by 10 points, the biggest single move available.
ValuationCurrently 36/100 (P/E 33 · EV/EBITDA 26.1). Taking it to 100 would lift the balanced score by 9 points, the next biggest.
ValuationCurrently 20/100 (P/E 53 · EV/EBITDA 38.0). Taking it to 100 would lift the balanced score by 10 points, the biggest single move available.
GrowthCurrently 53/100 (—). Taking it to 100 would lift the balanced score by 6 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 16, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.